Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 148

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 148
---
its products by these service providers could result in lower test volume. DiamiR’s business may suffer from the repetition of the
process and increased costs.

DiamiR may use third party collaborators to help us develop, validate, or commercialize any new products, and its ability to commercialize such products could be impaired or delayed if these collaborations are unsuccessful.

DiamiR may pursue strategic
collaborations for the development, validation, and commercialization of any new diagnostic products it may develop. In any future third
party collaboration, DiamiR may be dependent upon its collaborators performing their responsibilities and their cooperation. DiamiR cannot
control the amount of time and effort its collaborators will devote to performing their responsibilities under DiamiR’s agreements
with them. The development, validation and commercialization of its potential products may be delayed if collaborators fail to fulfill
their responsibilities in a timely manner or in accordance with regulatory requirements or if they breach or terminate their collaboration
agreements with DiamiR. In addition, a failure by third parties to perform their obligations in compliance with regulatory requirements
may cause DiamiR’s development, validation, or commercialization of new products to fail to meet regulatory requirements, which
may require it to repeat the process. If these third parties do not successfully carry out their contractual duties or meet expected deadlines,
DiamiR may be unable to obtain regulatory approval for or commercialize its future products. Furthermore, disputes with its collaborators
could also impair DiamiR’s reputation or result in development delays, decreased revenues and litigation expenses.

If DiamiR cannot enter into new clinical study collaborations, its product development and subsequent commercialization could be delayed.

Historically, DiamiR has entered
into clinical study collaborations with academic and medical institutions for access to clinical samples and expertise related to its
tests and services, and its success in the future depends in part on its ability to enter into additional collaborations with highly regarded
institutions. This can be difficult due to internal and external constraints placed on these organizations, and on occasion DiamiR key
contact may leave the organization. Some organizations may limit the number of collaborations they have with any one company, so as to
not be perceived as biased or conflicted. Organizations may also have insufficient administrative and related infrastructure to enable
collaboration with many companies at once, which can extend the time it takes to develop, negotiate, and implement a collaboration. Moreover,
it may take longer to obtain the samples DiamiR needs which could delay its trials, publications,